Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Waylivra (volanesorsen) 285 mg solution for injection in pre-filled syringe {equilateral_black_triangle}

Active Ingredient:
volanesorsen sodium
Company:  
Akcea Therapeutics UK Ltd See contact details
ATC code: 
C10AX18
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Waylivra Patient and Carer Guide

Waylivra risk minimisation guide for patients and carers.
{pdf_link}

Waylivra Risk Management HCP Guide

{healthcare_pro_orange} For Healthcare Professionals
Risk Minimisation Guide for Healthcare Professionals.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Akcea Therapeutics UK Ltd
Company image
Address
1st Floor West, Davidson House, Forbury Square, Reading, Berkshire, RG1 3EU, UK
Medical Information Direct Line
+44 (0) 800 111 4754
Medical Information e-mail
[email protected]